Clinical trial
An Exploratory Clinical Study of Keynatinib in Relapsed/Refractory B-cell Lymphoma
NCT04807881 is registered in ClinicalTrials.gov with Medolution Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory Clinical Study of Keynatinib in Relapsed/Refractory B-cell Lymphoma
- Lead sponsor
- Medolution Ltd.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 24, 2020
- Completion date
- April 10, 2028
- Enrollment
- 75 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.